Woodline Partners’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
Other funds holding RLMD
JT
SCM
VA
SSC
JHC
O
Woodline Partners's RLMD Position: Q2 2026 in Review
Woodline Partners reduced its Relmada Therapeutics (RLMD) stake by 22% in Q2 2026, selling an estimated $647K and leaving 328,421 shares worth $2.27M. The position accounts for 0.01% of the portfolio, ranked #823.
Woodline Partners first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.93M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.
- Woodline Partners held 328,421 shares of Relmada Therapeutics worth $2.27M as of Q2 2026.
- Woodline Partners sold 92,631 Relmada Therapeutics shares in Q2 2026, an estimated $647K.
- Relmada Therapeutics made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #823 holding.
- Woodline Partners first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
- Woodline Partners's Relmada Therapeutics position peaked at $2.93M in Q1 2026.
- 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.